| Literature DB >> 33921176 |
Qinghua Wang1, Jingwei Chen1, Dexiang Wang1,2,3, Minghui Shen4, Huilong Ou1, Jing Zhao1,2,3, Ming Chen1,2,3, Guoliang Yan5, Jun Chen1,2,3.
Abstract
Uncontrolled bleeding is the main cause of mortality from trauma. Collagen has been developed as an important hemostatic material due to its platelet affinity function. A bath sponge skeleton is rich in collagen, also known as spongin. To understand the hemostatic effect of spongin, spongin materials, SX, SFM and SR were prepared from the bath sponge Spongia officinalis, and hemostatic experiments were performed. The SX, SFM and SR were significantly better than the positive control, type I collagen, in shortening the whole blood clotting time in vitro and hemostasis upon rat tail amputation. In a hemostatic experiment of rabbit common carotid artery injury, the hemostatic time and 3 h survival rate of the SFM group were 3.00 ± 1.53 min and 100%, respectively, which are significantly better than those of the commercial hemostat CELOX-A (10.33 ± 1.37 min and 67%, respectively). Additionally, the SFM showed good coagulation effects in platelet-deficient blood and defibrinated blood, while also showing good biocompatibility. Through a variety of tests, we speculated that the hemostatic activity of the SFM is mainly caused by its hyperabsorbency, high affinity to platelets and high effective concentration. Overall, the SFM and spongin derivates could be potential hemostatic agents for uncontrolled bleeding and hemorrhagic diseases caused by deficiency or dysfunction of coagulation factors.Entities:
Keywords: Spongia officinalis; biocompatibility; hemostasis; platelet; spongin
Year: 2021 PMID: 33921176 PMCID: PMC8071530 DOI: 10.3390/md19040220
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Extraction process and characteristics of spongin material. (a) Schematic representation showing the preparation of samples. (b) Sponge weight and hydroxyproline content after each step of separation and purification. Columns show changes in weight and lines show changes in hydroxyproline content. (c) 10% SDS polyacrylamide gel electrophoresis pattern of SR. (d) Fourier transform infrared spectra of the SFM and SR. SEM photographs of the SX (e), SFM (f) and SR (g).
Figure 2In vitro blood coagulation. (a) The effects of contents of the SX, SFM, SR, and type I collagen on whole blood clotting. (b) Clotting time of 13 mg/mL SX, SFM, SR and type I collagen to whole blood. (c) Photographs of the coagulation effect of blank, SX, SFM, SR and type I collagen in PDB. (d) The effects of contents of the SX and SFM on PDB clotting. (e) Photographs of the coagulation effect of blank, SX, SFM, SR and type I collagen in DSB. (f) The effects of contents of the SFM and SR on DSB clotting. ** p < 0.01 and *** p < 0.001.
Figure 3Hemostasis in rat tail amputation. (a) Schematic diagram of rat tail amputation. (b) Hemostatic time and (c) blood loss in the rat tail amputation model. (d–h) Picture of hemostasis with each material ((d): blank; (e): SX; (f): SFM; (g): SR; and (h): type I collagen). * p < 0.05, ** p < 0.01 and *** p < 0.001.
Figure 4Hemostasis in rabbit′s common carotid artery incision. (a) Schematic diagram of New Zealand White Rabbit. (b) Exposing common carotid artery. (c) CELOX-A stopped the bleeding. (d) SFM stopped the bleeding. (e) Hemostatic time after treated with different samples. (f) Blood loss after treated with different samples. (g) Three-hour survival curve. * p < 0.05, ** p < 0.01 and *** p < 0.001.
Figure 5Platelets and RBCs adhered to the surface of the SFM. (a) Primitive morphology of platelets. (b) Platelets adhered to and aggregated on the SFM. (c) Original morphology of RBCs. (d) RBCs adhered to and aggregated on the SFM. (e) Number of platelets adhered to SFM and type I collagen after incubated for 15 min in PRP; (f) RBCs aggregation on SFM and type I collagen after incubation for 10 min. ** p < 0.01 and *** p < 0.001. (g) Schematic illustration showing the potential hemostatic mechanisms of SFM.
Figure 6Biocompatibility of the SFM. (a–f) Image of L929 cells in 96-well plates cultured in the media with 0, 0.625, 1.25, 2.5, 5 and 10 mg/mL SFM, respectively. (g) Cytotoxic effects of the control and different doses of SFM after 24 h. Data represent the mean ± SD (n = 3). (h) Hemolytic percentage of the sample. (i) Photographs from hemolytic activity assay of the sample using PBS as negative control and TX-100 as positive control. (TX-100: 0.1% triton-X100; Type I: type I; collagen; PBS: phosphate buffered saline).